Risk factors for thromboembolic events in patients hospitalized for COVID-19 pneumonia in a general ward and requiring treatment with oxygen

Author:

Degrave Raphaël1ORCID,Murris Juliette234,Charles-Nelson Anaïs56,Hermine Olivier78,Porcher Raphaël9,Ravaud Philippe9,Mariette Xavier1011,Tharaux Pierre-Louis12,Resche-Rigon Matthieu1314,Sanchez Olivier15,Katsahian Sandrine23516,Arlet Jean-Benoît17,

Affiliation:

1. Service de Médecine Interne 2, Hôpital Pitié Salpétrière , Paris, 75013 , France

2. INSERM, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris Cité , Paris, 75006 , France

3. Inria, HeKA, PariSantéCampus , Paris, 75015 , France

4. RWE & Data, Pierre Fabre , Hauts-de-Seine, Boulogne-Billancourt, 92100 , France

5. INSERM, Centre d’Investigation Clinique 1418 Épidémiologie Clinique , Paris, 75015 , France

6. Unité de Recherche Clinique, AP-HP, Hôpital Européen Georges-Pompidou , Paris, 75015 , France

7. Service d’hématologie, Hôpital Necker, AP-HP , Paris, 75015 , France

8. Institut Imagine, Université Paris-Cité, INSERM UMR1183 , Paris, 75015 , France

9. Center of Research Epidemiology and Statistics (CRESS), Université Paris-Cité, INSERM U1153 , Paris, 75004, France

10. Service de Rhumatologie, Hôpital Bicêtre , AP-HP, Le Kremlin-Bicêtre, 94270 , France

11. INSERM UMR1184, Université Paris-Saclay , Le Kremlin-Bicêtre, 94270 , France

12. Paris Cardiovascular Center–PARCC, Université de Paris, INSERM , Paris, 75015 , France

13. Université Paris-Cité, ECSTRRA Team-CRESS-UMR 1153, INSERM , Paris, 75010 , France

14. URC Saint-Louis , AP-HP, Hôpital Saint-Louis, Paris, 75010 , France

15. Service de Pneumologie, Université Paris-Cité , Hôpital Européen Georges Pompidou, Paris, 75015 , France

16. Unité de Recherche Clinique, APHP Centre, AP-HP, Hôpital Européen Georges-Pompidou , Paris, 75015 , France

17. Service de Médecine Interne, Hôpital Européen Georges Pompidou, AP-HP, Université Paris-Cité , Paris, 75015 , France

Abstract

Abstract Purpose To assess risk factors for arterial and venous thromboses (AVT) in patients hospitalized in general wards for COVID-19 pneumonia and requiring oxygen therapy. Methods Our study was based on three randomized studies conducted as part of the CORIMUNO-19 platform in France between 27 March and 26 April 2020. Adult inpatients with COVID-19 pneumonia requiring at least 3 l/min of oxygen but not ventilation were randomized to receive standard care alone or standard care plus biologics. Patients were followed up for 3 months, and adverse events were documented. Risk factor for AVT and bleeding was identified by analyzing clinical, laboratory, and treatment data at baseline among the 315 patients with complete datasets. A Fine and Gray model was used to take account of competing events. Results During the 3-month follow-up period, 39 AVT occurred in 38 (10%) of the 388 patients: 26 deep vein thromboses and/or pulmonary embolisms in 25 (6%) patients, and 14 arterial thrombotic events in 13 (3%) patients. A history of diabetes at inclusion [sHR (95% CI) = 2.65 (1.19–5.91), P = .017] and the C-reactive protein (CRP) level (sHR = 1 [1–1.01], P = .049) were significantly associated with an elevated risk of thrombosis. Obesity was not associated with a higher risk of thrombosis (sHR = 1.01 [0.4–2.57], P = .98). The CRP level and diabetes were not risk factors for hemorrhage. Conclusion Among patients hospitalized in general wards for COVID-19 pneumonia during the first wave of the epidemic, diabetes (but not obesity) and a high CRP level were risk factors for AVT. The use of higher doses of anticoagulant in these high-risk patients could be considered.

Funder

Programme Hospitalier de Recherche Clinique

Foundation for Medical Research

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Reference22 articles.

1. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial;Hermine;JAMA Intern Med,2021

2. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial;CORIMUNO-19 Collaborative group;Lancet Rheumatol,2022

3. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet;CORIMUNO-19 Collaborative group;Respir Med,2021

4. Thrombosis in hospitalized patients with COVID-19 in a New York City health system;Bilaloglu;JAMA,2020

5. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study;Katsoularis;BMJ,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3